Compare CPRX & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | ASH |
|---|---|---|
| Founded | 2002 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 2006 | 2016 |
| Metric | CPRX | ASH |
|---|---|---|
| Price | $31.45 | $66.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $35.00 | ★ $65.57 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 0.50 | 0.08 |
| Revenue | $119,072,803.00 | ★ $1,824,000,000.00 |
| Revenue This Year | $9.20 | $2.58 |
| Revenue Next Year | $10.51 | $4.28 |
| P/E Ratio | ★ $62.94 | $802.88 |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $46.30 |
| 52 Week High | $32.56 | $68.26 |
| Indicator | CPRX | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 71.22 | 63.25 |
| Support Level | $31.25 | $58.70 |
| Resistance Level | $32.56 | $68.26 |
| Average True Range (ATR) | 0.04 | 2.11 |
| MACD | -0.09 | -0.13 |
| Stochastic Oscillator | 70.59 | 68.19 |
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.